| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/31/2004 | EP1401861A2 Cads as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401859A2 Chimeric flavivirus vectors |
| 03/31/2004 | EP1401855A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 03/31/2004 | EP1401853A1 Modulators of pharmacological agents |
| 03/31/2004 | EP1401840A1 Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines |
| 03/31/2004 | EP1401837A1 Purine derivatives as a2b adenosine receptor antagonists |
| 03/31/2004 | EP1401833A2 Chemical derivatives and the use thereof as an anti-elomerase agent |
| 03/31/2004 | EP1401831A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 03/31/2004 | EP1401824A2 Aromatic hydroxamic acid derivatives useful as hdac inhibitors |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401818A2 Targeted multivalent macromolecules |
| 03/31/2004 | EP1401809A1 Tryptase inhibitors |
| 03/31/2004 | EP1401806A1 Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| 03/31/2004 | EP1401801A1 Selective androgen receptor modulators and methods of use thereof |
| 03/31/2004 | EP1401506A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
| 03/31/2004 | EP1401484A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| 03/31/2004 | EP1401483A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases |
| 03/31/2004 | EP1401481A1 Mucosal repair by tff dimer peptides |
| 03/31/2004 | EP1401480A2 Use of endostatin in the treatment of ocular neovascularization |
| 03/31/2004 | EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 03/31/2004 | EP1401476A2 Igf antagonist peptides |
| 03/31/2004 | EP1401475A2 Prmts as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401473A2 Transporters comprising spaced arginine moieties |
| 03/31/2004 | EP1401472A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 03/31/2004 | EP1401470A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 03/31/2004 | EP1401469A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 03/31/2004 | EP1401467A1 Alpha-fetoprotein peptides and uses thereof |
| 03/31/2004 | EP1401461A2 Selective cox-2 inhibition from edible plant extracts |
| 03/31/2004 | EP1401460A2 Selective cox-2 inhibition from plant extracts |
| 03/31/2004 | EP1401458A2 Composition consisting of phy906 and chemotherapeutic agents |
| 03/31/2004 | EP1401453A2 Protease inhibitors |
| 03/31/2004 | EP1401449A1 Tetracyclic compounds as pde5-inhibitors |
| 03/31/2004 | EP1401447A2 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therapy of diseases associated therewith |
| 03/31/2004 | EP1401446A1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
| 03/31/2004 | EP1401443A1 Novel anti-infectives |
| 03/31/2004 | EP1401438A1 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| 03/31/2004 | EP1401433A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 03/31/2004 | EP1401431A2 Human growth hormone antagonists |
| 03/31/2004 | EP1401429A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 03/31/2004 | EP1401427A2 Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them |
| 03/31/2004 | EP1401426A1 Ptpase inhibitors and method of using same |
| 03/31/2004 | EP1401425A1 Organometallic anti-tumour agent |
| 03/31/2004 | EP1401420A2 Perturbed membrane-binding compounds |
| 03/31/2004 | EP1401412A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 03/31/2004 | EP1401396A2 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 03/31/2004 | EP1401393A2 No-synthase inhibitor and use thereof |
| 03/31/2004 | EP1401377A2 Methods for treating cancer |
| 03/31/2004 | EP1401376A2 Colloidal metal compositions and methods |
| 03/31/2004 | EP1401375A2 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling |
| 03/31/2004 | EP1401282A1 Stem cell differentiation |
| 03/31/2004 | EP1401281A2 Toll/interleukin-1 receptor adaptor protein (tirap) |
| 03/31/2004 | EP1294742B1 Urokinase inhibitors |
| 03/31/2004 | EP1232174A4 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 03/31/2004 | EP1232144B1 Novel il-8 receptor antagonists |
| 03/31/2004 | EP1181318B1 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 03/31/2004 | EP1177186B1 Ureas and their use as cell adhesion modulators |
| 03/31/2004 | EP1121349B1 Substituted thiadiazolsulfonamides used as interleukin-1-beta inhibitors |
| 03/31/2004 | EP1049484B1 Use of il-11 to enhance cell mediated immunity for treating various viral and parasitic infections and cancer |
| 03/31/2004 | EP1025098B1 Benzothiophenes |
| 03/31/2004 | EP1003720B1 Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| 03/31/2004 | EP0784677B1 Inhibitor of stem cell proliferation and uses thereof |
| 03/31/2004 | EP0777484B1 Intravenous alendronate formulations |
| 03/31/2004 | EP0735818B1 MACROPHAGE INFLAMMATORY PROTEINS MIP-3, MIP-4 AND MIP-1gamma |
| 03/31/2004 | CN1486368A Methods for the production of multimeric proteins, and related compositions |
| 03/31/2004 | CN1486319A Synthesis of temozolomide and analogs |
| 03/31/2004 | CN1486313A Compounds for use in the treatment of skin conditions |
| 03/31/2004 | CN1486312A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486311A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486310A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486193A Effective antitumour treatments |
| 03/31/2004 | CN1486192A Binding domain-immunoglobulin fusion proteins |
| 03/31/2004 | CN1486191A Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| 03/31/2004 | CN1486190A Compositions containing an active fraction isolated from scutellariae barbatae and methods of use |
| 03/31/2004 | CN1485327A Tiemomium azoleamine-8-carboxylic acid ester and 8-amide derivatives,its synthesizing method and application in producing anticancer preparation |
| 03/31/2004 | CN1485087A Medicine for curing cancer, the preparation process and the application thereof |
| 03/31/2004 | CN1485083A Capsule for thyroid cancer / tumor and lymph node |
| 03/31/2004 | CN1485072A Coix seed oil soft capsule for curing prostate diseases and the application thereof |
| 03/31/2004 | CN1485071A Medicine for curing hydrocephalus, brain abscess and brain tumor and preparation process thereof |
| 03/31/2004 | CN1485029A Retinoic acid and the like oral formulation |
| 03/31/2004 | CN1143865C Tumor necrosis factor - ª‡inhibiting peptide and the application thereof |
| 03/31/2004 | CN1143859C Camptothecin derivative and its preparation |
| 03/31/2004 | CN1143858C 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
| 03/31/2004 | CN1143854C Novel 2-(iminomethyl) amino-phenyl derivatives,the preparation thereof, application as medicines and pharmaceutical compositions containing same |
| 03/31/2004 | CN1143847C Thio-oxindole derivatives |
| 03/31/2004 | CN1143618C Precise efficiency assay methods for active agents including chemotherapeutic agents |
| 03/30/2004 | US6713633 Compounds capable of cleaving double-stranded DNA and method of utilization of the same |
| 03/30/2004 | US6713623 Useful as intermediates in the synthesis of biologically active compounds |
| 03/30/2004 | US6713616 Detecting binding |
| 03/30/2004 | US6713607 Effector proteins of Rapamycin |
| 03/30/2004 | US6713508 Such as 7-(3-(3-trifluoromethyl-7-propyl-6-benz-(4,5)-isoxazoloxy)propoxy)-2 -ethylchromane-2-carboxylic acid which are potent agonists of peroxisome proliferator activated receptor |
| 03/30/2004 | US6713507 Ether compounds and compositions for cholesterol management and related uses |
| 03/30/2004 | US6713490 6-(2-(4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl)-1-hydroxy -ethyl)-3,4-dihydro-2(1h)-quinolinone; reduced inhibitory activity at herg (human ether-a-go-go related gene) potassium channel |
| 03/30/2004 | US6713487 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition |
| 03/30/2004 | US6713485 Antiproliferative agents; side effect reduction |
| 03/30/2004 | US6713484 Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| 03/30/2004 | US6713482 Such as (e)-1-(2-pyridyl)-2-styryl-1h-benzimidazole; antiinflammatory and analgesic agents; prostaglandin inhibitors |
| 03/30/2004 | US6713480 Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| 03/30/2004 | US6713478 Cyclocarbamate derivatives as progesterone receptor modulators |
| 03/30/2004 | US6713454 Prodrugs of etoposide and etoposide analogs |
| 03/30/2004 | US6713446 Boronic acid compounds obtained by lyophilization of an aqueous mixture of the boronic acid compound and a sugar having at least two hydroxyl groups; shelf life |